An escalating pandemic by the novel SARS-CoV-2 virus is impacting global health and effective therapeutic options are urgently needed. We evaluated the in vitro antiviral effect of compounds that were previously reported to inhibit coronavirus replication and compounds that are currently under evaluation in clinical trials for SARS-CoV-2 patients. We report the antiviral effect of remdesivir, lopinavir, homorringtonine, and emetine against SARS-CoV-2 virus in Vero E6 cells with the estimated 50% effective concentration at 23.15 μM, 26.63 μM, 2.55 μM and 0.46 μM, respectively. Ribavirin or favipiravir that are currently evaluated under clinical trials showed no inhibition at 100 μM. Synergy between remdesivir and emetine was observed, and remdesivir at 6.25 μM in combination with emetine at 0.195 μM may achieve 64.9% inhibition in viral yield. Combinational therapy may help to reduce the effective concentration of compounds below the therapeutic plasma concentrations and provide better clinical benefits.

中文翻译：

---

Remdesivir，lopinavir，emetine和homoharringtonine在体外抑制SARS-CoV-2复制。

由新型SARS-CoV-2病毒引起的大流行正在影响全球健康，迫切需要有效的治疗选择。我们评估了先前报道可抑制冠状病毒复制的化合物和目前正在SARS-CoV-2患者临床试验中评估的化合物的体外抗病毒作用。我们报告了雷莫昔韦，洛匹那韦，高丝氨酸和曲美汀对SARS-CoV-2病毒在Vero E6细胞中的抗病毒作用，估计有效浓度分别为23.15μM，26.63μM，2.55μM和0.46μM。目前在临床试验中评估的利巴韦林或利巴韦拉韦在100μM时未显示抑制作用。观察到remdesivir和Emetine之间存在协同作用，6.25μM的remdesivir与0.195μM的Emetine联用可实现64.9％的病毒产量抑制。